CAPTRUST Financial Advisors’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
Other funds holding ALDX
KCM
KCM
6CM
CAPTRUST Financial Advisors's ALDX Position: Q3 2026 in Review
CAPTRUST Financial Advisors reduced its Aldeyra Therapeutics (ALDX) stake by 30% in Q3 2026, selling an estimated $24.9K and leaving 36,202 shares worth $44.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3263.
CAPTRUST Financial Advisors first reported a position in ALDX in Q4 2021 and has held it in 17 quarters since. The position peaked at $277K in Q3 2025. 96 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.
- CAPTRUST Financial Advisors held 36,202 shares of Aldeyra Therapeutics worth $44.5K as of Q3 2026.
- CAPTRUST Financial Advisors sold 15,576 Aldeyra Therapeutics shares in Q3 2026, an estimated $24.9K.
- Aldeyra Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #3263 holding.
- CAPTRUST Financial Advisors first reported a position in Aldeyra Therapeutics in Q4 2021 and has held it in 17 quarters since.
- CAPTRUST Financial Advisors's Aldeyra Therapeutics position peaked at $277K in Q3 2025.
- 96 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.